Detection of CYP3A4* 1B and CYP3A4* 2 polymorphisms by RFLP. Distribution frequencies in a Mexican population

Clinical Genetics

Volumn 66, Issue 2, 2004, Pages 166-168

  Reyes Hernandez O D ^b   Arteaga Illan G ^b   Elizondo, Guillermo ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; GENOMIC DNA; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; PRIMER DNA;

ALLELE; DNA DETERMINATION; ETHNOLOGY; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; LETTER; MEXICO; POPULATION DISTRIBUTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; GENE STRUCTURE; GENETIC POLYMORPHISM; GENETICS; MALE; METABOLISM; POPULATION GENETICS;

ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; GENE COMPONENTS; GENETICS, POPULATION; HUMANS; MALE; MEXICO; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 4344607693     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2004.00286.x     Document Type: Letter

References (16)

1. Kolars JC, Benedict P, Schmiedlin-Ren P, Watkins PB. Aflatoxin B1-adduct formation in rat and human small bowel enterocytes. Gastroenterology 1994: 106: 433-439.
2. Shimada T, Yamazaki H, Mimura M et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270: 414-423.
3. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999: 39: 1-17.
4. Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 1997: 346: 161-169.
5. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995: 104: 1-8.
6. Forrester LM, Neal GE, Judah DJ et al. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc Natl Acad Sci USA 1990: 87: 8306-8310.
7. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998: 38: 389-430.
8. Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000: 67: 48-56.
9. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med 2003: 41: 1345-1350.
10. Paris PL, Kupelian PA, Hall JM et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999: 8: 901-905.
11. Rebbeck TR, Jaffe JM, Walker AH et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998: 90: 1225-1229.
12. Kittles RA, Chen W, Panguluri RK et al. CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 2002: 110: 553-560.
13. Cavalli SA, Hirata MH, Hirata RD. Detection of MboII polymorphism at the 5′ promoter region of CYP3A4. Clin Chem 2001: 47: 348-351.
14. Walker AH, Jaffe JM, Gunasegaram S et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat 1998: 12: 289.
15. Tayeb MT, Clark C, Ameyaw MM et al. CYP3A4 promoter variant in Saudi, Ghanaian and Scottish Caucasian populations. Pharmacogenetics 2000: 10: 753-756.
16. Zeigler-Johnson CM, Walker AH, Mancke B et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 2002: 54: 13-21.